AUTHOR=Wang Haipeng , Ding Lin , Tian Liwen , Tian Yutian , Liao Lin , Zhao Junyu 

TITLE=Empagliflozin reduces diffuse myocardial fibrosis by extracellular volume mapping: A meta-analysis of clinical studies

JOURNAL=Frontiers in Endocrinology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.917761

DOI=10.3389/fendo.2022.917761

ISSN=1664-2392

ABSTRACT=<sec><title>Objective</title><p>The aim of the study was to evaluate the effect of empagliflozin on diffuse myocardial fibrosis by cardiac magnetic resonance (CMR) T1 mapping.</p></sec><sec><title>Research methods and procedures</title><p>Databases including PubMed, Cochrane library, Embase, and Sinomed for clinical studies of empagliflozin on myocardial fibrosis were searched. Two authors extracted the data and evaluated study quality independently. Weighted mean difference (WMD) and 95% confidence intervals (CI) were used for continuous variables. Review Manager 5.3 was used to performed the analysis.</p></sec><sec><title>Results</title><p>Six studies were included in this meta-analysis. One of the six studies was assessed as poor quality by the assessment of methodological quality; however, the remaining five studies were considered good. The WMD value of △extracellular volume (ECV) was merged by the fixed-effect model, and the pooled effect size was -1.48 (95% CI -1.76 to -1.21, <italic>P</italic> &lt; 0.00001), which means in favor of empagliflozin. Heterogeneity analysis did not find any heterogeneity (chi<sup>2</sup> = 0.39, <italic>P</italic> = 0.82, <italic>I</italic><sup>2</sup> = 0%). In addition, empagliflozin had a tendency to reduce ECV compared to treatment before with no statistical significance (WMD = -0.29, 95% CI -1.26 to 0.67, <italic>P</italic> = 0.55; heterozygosity test, chi<sup>2</sup> = 2.66, <italic>P</italic> = 0.45, <italic>I</italic><sup>2</sup> = 0%). The WMD value of △native T1 was also merged by the fixed-effect model, but the pooled effect size showed neither statistical difference between empagliflozin and placebo treatment (WMD = -5.40, 95% CI -21.63 to 10.83, <italic>P</italic> = 0.51) nor heterogeneity (chi<sup>2</sup> = 0.05, <italic>P</italic> = 0.83, <italic>I</italic><sup>2</sup> = 0%).</p></sec><sec><title>Conclusions</title><p>Empagliflozin has cardiovascular benefits by reducing diffuse myocardial fibrosis. ECV could act as a non-invasive imaging tool to assess diffuse myocardial fibrosis and monitor disease progression.</p></sec><sec><title>Systematic Review Registration</title><p><uri xlink:href="https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=324804" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=324804</uri>, identifier: CRD42022324804</p></sec>